AzTrials
AzTrials

Non-Small Cell Lung CancerPhase 3NCT06031558

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

A Phase 3 study testing SY-5007 in people with Non-Small Cell Lung Cancer, run by Shouyao Holdings (Beijing) Co. LTD at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a phase III, open-label, single-arm, multicenter study designed to evaluate the anti-tumor activity and safety of SY-5007 administered orally to participants with locally advanced or metastatic RET-positive NSCLC. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Non-Small Cell Lung Cancer
What is being tested?
SY-5007
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteChina
Study dates
31 Oct 2023to 20 Jun 2026
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female, at least 18 years old.
  • Histologically or cytologically confirmed diagnosis of locally advanced (with a tumor lesion that cannot be eradicated by surgery or radiotherapy as assessed by the investigators) or metastatic NSCLC.
  • No prior systemic antitumor therapy for locally advanced or metastatic NSCLC (Note: enrollment is permitted in the following 2 situations: 1) received only adjuvant therapy and the end of treatment was ≥ 6 months prior to the first dose; 2) received only radical radiotherapy and the end of treatment was ≥ 6 months prior to the first dose).
  • The patient's tumor tissue or blood sample test result meets 1 of the following two criteria: a. Previous tumor tissue or blood samples are confirmed as RET fusion positive by local laboratory testing. b. If there is no previous RET fusion positive test report, a compliant tumor tissue or blood sample is required to be provided at the central laboratory, using a next-generation sequencing (NGS)-based assay to confirm RET fusion positive.
  • Patients have at least one measurable lesion per RECIST version 1.1. (except for patients with measurable lesions in the brain only) (Note: a lesion that has been treated with radiotherapy or localized therapy is generally not considered a measurable lesion unless there is definitive progression of that lesion).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
Show all 18Show fewer
  • Life expectancy of at least 3 months.
  • Patients must have adequate organ function as defined in the below:
  • Bone marrow function:
  • patients must not have received any blood products, hematopoietic cell growth factors or other blood medications for at least 7 days prior to the first dose, and have a blood count: absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L, platelet (PLT) count ≥ 75 x 10^9 /L, and hemoglobin (Hb) ≥ 90 g/L;
  • Liver function:
  • total bilirubin (TBIL) ≤ 1.5 times upper limit of normal (ULN) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN in the absence of liver metastases; in the presence of liver metastases, both AST and ALT ≤ 5.0 times ULN and TBIL ≤ 3 times ULN;
  • Renal function:
  • creatinine clearance (Ccr) ≥ 50 mL/min.
  • Coagulation function:
  • prothrombin time (PT) or International Normalized Ratio (INR) ≤ 1.5 times ULN.
  • Patients can swallow the drug orally and are able to comply with follow-up visit requirements.
  • Male and female patients of childbearing potential must be willing to abstain completely or agree to use an appropriate method of contraception for the duration of the study and for at least 3 months after the last dose of study medication.

Who cannot join

  • Patients carried known major driver genetic alterations other than RET. e.g. EGFR, MET, ALK, ROS1, NTRK, BRAF V600, KRAS G12C, etc. (If a patient has a co-mutation, discuss with the investigators whether enrollment is possible).
  • History of allergy to any components or excipients of SY-5007 tablets.
  • Patients with malignancies other than NSCLC treated in this study (except: malignancies that are cured and have not recurred within 2 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of the cervix or breast).
  • Patient has clinically symptomatic primary central nervous system (CNS) tumor, symptomatic CNS metastases, molluscum contagiosum, or untreated spinal cord compression; exclusion: patient has stable CNS disease (no evidence of progression as determined by imaging for at least 4 weeks prior to the first dose and all neurological symptoms have returned to baseline levels), no evidence of new or enlarging brain metastases, and has not had CNS surgery or radiotherapy within 4 weeks prior to the first dose, has not undergone stereotactic radiosurgery within 2 weeks, and has discontinued or stabilized steroid dosing within 2 weeks.
  • Comorbidities of the following symptoms or conditions prior to the first dose that remain poorly controlled with optimal therapy:
  • active uncontrolled systemic bacterial, viral, or fungal infections; pleural, abdominal, or pericardial effusions that are poorly controlled with interventions (e.g., drainage) (poorly controlled is defined as growth that is significant and symptomatic within 2 weeks of fluid collection and requires re-puncturing or other interventions); poorly controlled diabetes mellitus [fasting blood glucose ≥ 10 mmol/L and/or glycated hemoglobin (HbA1c) ≥ 8%]; uncontrolled symptomatic hyperthyroidism or hypothyroidism as assessed by the investigators; uncontrolled electrolyte disorders (e.g., hyper/hypocalcemia, hyper/hypomagnesemia, hyper/hypokalemia) as assessed by the investigators; clinically significant severe gastrointestinal disorders as assessed by the investigators, including active ulcerative colitis Crohn's disease, peptic ulcers, or previous surgical procedures that may have significantly interfered with the absorption of the drug.
Show all 18Show fewer
  • Presence of serious cardiovascular disease/abnormalities as indicated by any of the following:
  • a QTcF > 470 msec (females) or > 450 msec (males) using the Fridericia formula for heart rate correction at screening, (If drug-induced prolongation of the QTcF is suspected, it is assessed by the investigators to be safe and manageable and may be corrected with medication and then enrolled.); left ventricular ejection fraction (LVEF) < 45%; myocardial infarction or unstable angina pectoris or clinically significant uncontrolled arrhythmia within 6 months prior to the first dose of the drug, including bradyarrhythmias (e.g., type II second or third-degree heart block) that may result in prolongation of the QTcF; classified as class III or IV according to New York Heart Association (NYHA) criteria Congestive heart failure; poorly controlled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg), history of unstable hypertension, or history of poor compliance with antihypertensive therapy.
  • Presence of active viral infection or history of:
  • Hepatitis B (Hepatitis B surface antigen [HBsAg] positive with HBV DNA test > 2 x 10^3 IU/mL, eligible for enrollment if re-tested to less than 2 x 10^3 IU/mL with regular antiviral therapy); positive test for Human Immunodeficiency Virus (HIV) at screening or a known history of other immune deficient disorders; a history of prior organ transplantation, hematopoietic stem cell or bone marrow transplantation therapy.
  • Presence of other lung diseases that require systemic treatment or are serious, such as active tuberculosis, interstitial lung disease, etc., which in the opinion of the investigators may influence the interpretation of the study results or put the patient at high risk.
  • Patients who had used or were unable to discontinue the following potent inhibitors or inducers of CYP3A4 during the study period within 2 weeks prior to the first dose. CYP3A4 potent inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, vinpocetine, voriconazole; and CYP3A4 potent inducers: carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin.
  • Palliative radiotherapy within 1 week prior to the first dose, or any lung radiotherapy with more than 30 Gy of radiation within 6 months prior to the first dose.
  • Major surgical procedure (except central venous catheterization, tumor puncture biopsy, and gastric tube placement) or significant trauma within 4 weeks prior to the first dose.
  • Participation in another clinical trial within 4 weeks prior to the first dose (note: except for those who are not using the investigational drug or investigational medical device; or those who have discontinued treatment from another clinical trial and are only being followed for subsequent survival) or are planning to participate in another clinical trial during the study period.
  • Serious arterial/venous thrombotic event within 1 year prior to the first dose, such as cerebrovascular accident, deep vein thrombosis, pulmonary embolism, or bleeding tendency within 30 days prior to the first dose, or risk of gastrointestinal bleeding as judged by the investigators.
  • Female patients who are pregnant or breastfeeding.
  • Any other conditions that, in the opinion of the investigators, makes participation in this clinical trial inappropriate.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433

Other trials in China

About this study

Official title: A Phase III, Open-Label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC.

This is a phase III, open-label, single-arm, multicenter study designed to evaluate the anti-tumor activity and safety of SY-5007 administered orally to participants with locally advanced or metastatic RET-positive NSCLC.

Read the detailed description

This study will enroll patients with locally advanced or metastatic RET-positive NSCLC. SY-5007 will be administered orally 160 mg twice daily in 28-day cycle continuously until disease progression, death, unacceptable toxicity, withdrawal of consent, or protocol-specified parameters. This study is designed to evaluate the anti-tumor activity (over response rate [ORR], disease control rate [DCR], duration of response [DOR], progression free survival [PFS] and overall survival [OS]) and safety of SY-5007 in patients.

Being tested
SY-5007
Keywords
SY-5007, RET-positive NSCLC, Locally advanced RET-positive NSCLC, Metastatic RET-positive NSCLC
Medical subject headings
Carcinoma, Non-Small-Cell Lung

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SY-5007Drug

    Also called SY-5007 tablets

    a RET selective Inhibitor

Study groups in NCT06031558
Study groupRoleWhat they receive
SY-5007ExperimentalSY-5007 will be given orally 160 mg twice daily in 28-day cycle continuously until disease progression, death, unacceptable toxicity, or withdraw consent in this study.
Receives: Drug: SY-5007

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of ORR by independent review committee (IRC).

    Defined as the number (%) of patients with measurable disease with response of complete response (CR) or partial response (PR) assessed by IRC according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Measured: Tumor scans performed at baseline then every 8 weeks up to 1 year, then every 12 weeks thereafter; up to 3 years.

Secondary outcomes (7)

  1. ORR as assessed by investigators.

    Defined as the number (%) of patients with measurable disease with response of CR or PR assessed by investigators according to RECIST version 1.1.

    Measured: Up to 3 years.

  2. DCR as assessed by investigators and IRC.

    Defined as the number (%) of patients who have a best overall response of CR or PR or stable disease (SD) according to RECIST 1.1.

    Measured: Up to 3 years.

  3. PFS as assessed by investigators and IRC.

    PFS is defined as the time from the date of randomization to progression of tumor as assessed by investigators or death from any cause on study.

    Measured: Up to 3 years.

  4. Time to response (TTR) as assessed by investigators and IRC.

    TTR is defined as the time from the date of randomization to the first response of CR or PR.

    Measured: Up to 3 years.

  5. DoR as assessed by investigators and IRC.

    DoR is defined as the time from first response until disease progression or death, whichever occurs first.

    Measured: Up to 3 years.

  6. Overall survival (OS).

    OS is defined as the time from the date of randomization until death due to any cause.

    Measured: Up to 3 years.

  7. Incidence of adverse events (AEs) and serious adverse events (SAEs).

    AEs are graded according to CTCAE v 5.0.

    Measured: From the screening period to 28 days after treatment completion, up to a maximum of approximately 3 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2023
  2. Study start31 Oct 2023
  3. Primary completion10 Apr 2025
  4. Study completion20 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single Group Assignment
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06031558
Sponsor's protocol ID
SY-5007-III-01
Status last verified
Jun 2026
First submitted
31 Aug 2023
Last updated
16 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing SY-5007 in people with Non-Small Cell Lung Cancer, run by Shouyao Holdings (Beijing) Co. LTD at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of ORR by independent review committee (IRC). (time frame: Tumor scans performed at baseline then every 8 weeks up to 1 year, then every 12 weeks thereafter; up to 3 years.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06031558.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in